Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016

Abstract

ObjectivesWe aimed to determine trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors (GI-NETs) from 1977 to 2016, and then analyze the potential risk factors including sex, age, race, grade, Socioeconomic status (SES), site, and stage.MethodsData were obtained from Surveillance, Epidemiology, and End Results Program (SEER) database. Kaplan-Meier survival analysis, relative survival rates (RSRs), and Cox proportional risk regression model were used to evaluate the relationship between these factors and prognosis.ResultsCompared with other sites, the small intestine and rectum have the highest incidence, and the appendix and rectum had the highest survival rate. The incidence was higher in males than in females, and the survival rate in males was close to females. Blacks had a higher incidence rate than whites, but similar survival rates. Incidence and survival rates were lower for G3&4 than for G1 and G2. Age, stage, and grade are risk factors.ConclusionsThis study described changes in the incidence and survival rates of GI-NETs from 1977 to 2016 and performed risk factor analyses related to GI-NETs.

Analysis of endoscopic salvage treatment of rectal neuroendocrine tumor; effective utilization of polypectomy

“…Although rectal neuroendocrine tumors (RNETs) are relatively uncommon, their incidence has increased due to widespread use of screening colonoscopy and advancements in endoscopic technology [1]. The majority of RNETs are detected at stage 1 or 2, featuring excellent long-term prognosis with 5-year survival rates ranging from 74-88% [1,10,11]. Typically, 80-90% of these tumors are less than 1 cm in size, are low grade, exhibit rare metastasis (< 3%), and are diagnosed early in a well-differentiated state con ned to the submucosa [4,12].…”

Current clinical application of lutetium‑177 in solid tumors (Review)

“…The most common NET subtype is the gastrointestinal pancreatic NET (GEP-NET) ( 36 ). An analysis of United States cancer data showed that the incidence of gastrointestinal neuroendocrine tumors has continuously increased each decade from 1977 to 2016( 37 ). Currently, surgery is the primary therapeutic method for GEP-NETs because most GEP-NETs are inert.…”

Lymph node ratio and hematological parameters predict relapse-free survival in Patients With high grade rectal neuroendocrine neoplasms after radical resection: A multicenter prognostic study

“…These neoplasms are mostly found in the gastrointestinal tract, pancreas, and lung [2], with the rectum being the third most frequent site of such tumors. The incidence of rectal neuroendocrine tumors has increased and was 1.3/100,000 from 2007-2016 [2][3]. Rectal neuroendocrine neoplasms (R-NENs) are classi ed into rectal neuroendocrine tumor (R-NET), rectal neuroendocrine carcinoma (R-NEC), and rectal mixed adeno-neuroendocrine carcinoma (R-MANEC) based on differentiation degree, mitotic count, and Ki-67 index.…”